Member Info for Harrogate4

Costa ------"Are we not allowed to go past 330p"

That's what it looks like (and has done for days)

Curious SP progression (or lack of it) and looking very controlled.

I wonder why.

Excellent postings Bella.

Could be you have hit the nail on the head here regarding financing.

Good luck to all holders for tomorrow.

Thanks

Jyee7 -------What's the gist of the article please.

Timster ------"What makes you think they are going to suddenly announce next week?"

I don't have a clue what Avacta are going to do next week ( for the avoidance of doubt).

B2HS2L ------"Summary - presently only CC Lists CAR-T skills, RNS's don't discuss them."

So, do we think CAR-T matters are more of a Red Herring rather than a left field Dark Horse?

Maybe an RNS either tomorrow or Tuesday before Business Update on 2nd July will decide?

The update could also just cofirm the Coris Bioconcept issue is now done and money heading into the Avacta coffers.

Dr. Christina Coughlin, on the other hand, has deep expertise in CAR-T and other cell therapies. She previously served as Chief Medical Officer at Tmunity Therapeutics, where she led the development of autologous CAR-T and TCR-T therapies. She also held leadership roles at Rubius Therapeutics and Immunocore, and was CEO of CytoImmune Therapeutics, a company developing CAR-NK cell therapies—a close cousin to CAR-T.

Could CAR-T be a left field dark horse here?

Touk -----"They haven’t said they haven’t"

Agreed, and as I recall CC's earlier work was very much concerned with CAR-T.

Hurst10 -----"The FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for currently approved BCMA- and CD19-directed CAR-T therapies, the agency said Thursday"

But Avacta don't have any of these do they?.

LLP -----"Probably a close call – Phillies at home to Padres on Tue and Wed, priorities?"

Always amazes me how much a game of rounders can grip a nation.

Each to their own though.

Presumably we are anticipating some sort of denouement moment around 2nd July involving link ups/licensing agreements/partnerships/etc with other players.

For what it's worth my money is on Novartis.

Why Novartis?

CC used to work with Novartis sometime in the 2010s I think probably in New Jersey but not sure.

Novartis is "just around the corner" from Avacta's premises in White City, London.

Novartis probably sees value in Avacta's tumour targeting platforms, especially for hard to treat cancers like SG Tumours, so a partnership or link up could be a wise move, particularly given the recent information in the 19th June RNS ( New Response in Phase 1b Trial).

As I recall, Bella was pretty sure that LDA would be pleasantly surprised with the Avacta Business update on AGM day and I am sure she is right to have that view.

On the other hand and for balance, I could be completely on the wrong track and the Business update could be more Affyxell focused.

We have been told they (Avacta) are going to give us a Business Update and I doubt it is just to confirm that things are continuing to go well and that they are all working hard and are busy.

We await 2nd July with interest.

AvctIPmatters ------"His responsibilities"

Limited applicants then.

Both should ensure the good progress here continues. Like the Price Waterhouse engagement in particular.

POSTI ------"what’s the crack"

Craic not crack.

Sandgrounded ------"-until they are admitted to AIM, which is EXPECTED to be at 08.00am today."

Guess that's the same for Interactive Investor and A J Bell?

The Au price looks likely to remain at high levels following the US bombing of the Iranian nuclear facilities.

Here it is:

"Avacta’s 19th June RNS announced a new partial response in a patient with metastatic salivary gland cancer during the Phase 1b trial of its lead candidate, FAP-Dox (AVA6000). This is significant because it adds to earlier data showing a 91% disease control rate and suggests continued antitumor activity in a cancer type with no preferred standard therapy.

From a market perspective, this kind of clinical progress—especially in a rare cancer with high unmet need—can act as an inflection point. It strengthens the therapeutic credibility of AVA6000 and supports Avacta’s broader pre|CISION® platform. Investors often interpret such updates as a de-risking event, which can drive renewed interest and upward momentum in the share price.

Indeed, following the RNS, Avacta’s share price rose from around 29.5p to 33p by the next trading day—a gain of over 11%3. That kind of move suggests the market saw the update as materially positive, especially given the company’s prior volatility and investor focus on clinical milestones."

"Bluebird Mining Ventures (BMV) is a UK-based gold mining company. Recently, they announced a bold new strategy: instead of keeping their profits in cash or reinvesting only in mining, they’re going to convert their gold revenues into Bitcoin and hold it as a long-term asset on their balance sheet2.

Think of it like this: just as companies might keep savings in gold or cash, BMV is choosing to save in Bitcoin — which they see as “digital gold.” They believe Bitcoin’s limited supply and independence from governments make it a strong hedge against inflation and global financial instability3.

As for whether it’s a good move — that depends on your perspective:

Pros: It positions BMV as a forward-thinking company, potentially attracting new investors who believe in Bitcoin’s future. Their stock price even jumped over 60% after the announcement3.

Risks: Bitcoin is still volatile. If its value drops significantly, BMV’s financial health could take a hit. Plus, this strategy is relatively new for traditional mining firms, so it’s uncharted territory.

In short: BMV is blending old-school gold with new-school crypto. It’s a bold bet — and one that could either pay off big or prove risky depending on how the Bitcoin market evolves."

"Delighted to be at #BiotechWeekBoston connecting with industry and highlighting the great progress preCISION continues to make in clinic." #AVCT

@avacta

#LetsDoThis

#PeptidesCreateHope

#HopeWithoutCompromise

10:32 PM · Jun 18, 2025

Nice to hear the news from CC, worthy of an RNS in the circumstances I would have thought.

·

PL75 --------"Are you expecting Bella news, what?"

Come again?